Draeger, Inc. recalled 431 units of the Vapor 2000 anesthetic vaporizer on November 24, 2025. A component of the devices contained impurities and did not meet specifications, posing a high hazard risk. Healthcare providers and patients should cease use immediately and follow recall instructions.
A certain component of affected devices was not delivered within specification and contained impurities.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Draeger, Inc. or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is the Draeger Vapor 2000 anesthetic vaporizer, Model No. M35054. Units were distributed worldwide, including multiple U.S. states such as California and Texas. The recall affects 431 units.
The recall stems from a component of the vaporizer that failed to meet specifications and contained impurities. This defect poses a significant health risk to patients undergoing anesthesia.
No specific injuries or incidents have been reported in connection with this recall. The FDA classified this recall as Class I, indicating a high risk to health.
Patients and healthcare providers should stop using the Draeger Vapor 2000 immediately. Contact Draeger, Inc. or your healthcare provider for further instructions and follow the recall process outlined in the notification letter.
For more information, contact Draeger, Inc. at their official website or refer to the recall notification letter. Additional details can be found on the FDA website.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.